• Kailera Therapeutics

  Participated · Series B · Oct 2025

  Kailera Therapeutics is advancing a differentiated portfolio of obesity treatments spanning both injectable and oral modalities. Its lead candidate, KAI-9531, is an injectable dual GLP-1/GIP receptor agonist that has shown potentially best-in-category weight-loss efficacy and is expected to enter global Phase 3 trials by the end of 2025. The company is also preparing KAI-7535, an oral small-molecule GLP-1 receptor agonist that achieved competitive weight loss in a Phase 2 study in China, for worldwide clinical development. Earlier-stage assets include KAI-4729, an injectable GLP-1/GIP/glucagon tri-agonist, and an oral tablet formulation of KAI-9531. Kailera additionally holds rights to new formulations and first-refusal options on selected metabolic assets from Hengrui. Headquartered in Waltham, Massachusetts, and San Diego, California, the company’s recent $600 million Series B financing provides the capital needed to progress its late-stage and early-stage programs toward commercialization.

• MindRhythm

  Participated · Seed · Aug 2021

  MindRhythm is a medical technology company focused on preventing neurological injury in stroke. Its Harmony device is a novel, non-invasive diagnostic medical device designed for use in EMS settings to rapidly identify potentially lethal large vessel occlusion (LVO) strokes. The company’s monitoring devices provide real-time prehospital visibility to life‑threatening situations so clinicians can intervene to prevent brain damage. MindRhythm was founded by world‑renowned experts with significant commercialization experience and is collaborating with the healthcare community to apply a STEMI‑style systematic approach to reducing time to stroke treatment. The recent funding will support completion of a clinical trial to demonstrate the device’s effectiveness in the EMS environment. The raise underscores the company’s focus on improving outcomes for all stroke patients given stroke’s high mortality and disability burden in the U.S.

• CG Oncology

  Participated · Series D · Dec 2020

  CG Oncology is an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer and is based in Irvine, Calif. Its lead asset, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy in a Phase 3 trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with pembrolizumab for the same indication and is being evaluated with nivolumab in other bladder cancer types. The company reports that the asset has shown clear signals of activity as a single agent and in combination. CG Oncology says it aims to advance its clinical programs toward FDA approval, emphasizing potential to address resistance mechanisms to approved immunotherapies and improve outcomes for bladder cancer patients. The recently announced financing will support continued development and regulatory advancement of its lead programs. CG Oncology develops oncolytic immunotherapies focused on urologic cancers, with an emphasis on bladder‑sparing approaches. Its lead candidate, CG0070, is an intravesically delivered oncolytic agent in a Phase 3 BOND3 monotherapy trial for BCG‑unresponsive NMIBC and a fully enrolled Phase 2 CORE1 combination study with pembrolizumab. The company has a clinical collaboration with Merck/MSD to evaluate the CG0070‑pembrolizumab combination. Interim Phase 2 data presented at SITC 2022 showed strong anti‑tumor activity and tolerability for the combination. CG0070 has been administered to over 200 patients and has demonstrated potential best‑in‑class efficacy and safety in monotherapy and strong response rates with checkpoint inhibitors. CG Oncology plans to use the new proceeds to advance its lead bladder cancer programs toward FDA approval and to expand development into first‑line BCG‑naïve intermediate‑risk NMIBC. The company has secured more than $200 million in total funding to date following the Series E close. CG Oncology, based in Irvine, Calif., is a clinical-stage biotechnology company focused on developing next-generation oncolytic immunotherapies. Its lead candidate, CG0070, is a selective oncolytic immunotherapy that completed a Phase 2 trial for high-grade NMIBC after BCG failure. The company is advancing multiple late-stage programs including a global Phase 3 trial (BOND3) of CG0070 monotherapy and a Phase 2 combination trial (CORE1) with pembrolizumab in BCG-unresponsive NMIBC. A Phase 1b study (CORE2) is also ongoing combining CG0070 with nivolumab as a neoadjuvant therapy for MIBC in cisplatin-ineligible patients. Management says the lead monotherapy program is advancing to a BLA. The company recently closed financing to support these clinical development programs. Cold Genesys is a clinical-stage biopharmaceutical company developing oncolytic immunotherapies, with lead candidate CG0070 targeting non-muscle invasive bladder cancer (NMIBC). CG0070 completed a Phase 2 single-arm, open-label, multicenter study (BOND2) and has demonstrated clinical safety and efficacy in over 100 patients to date for NMIBC. The company is also exploring CG0070 in combination with immune checkpoint modulators across different solid tumors and has a partnership with Merck to evaluate pembrolizumab (KEYTRUDA) plus CG0070 in a Phase 2 study. Cold Genesys recently closed a $22 million Series C preferred stock financing to accelerate its ongoing clinical programs and further advance CG0070. The round was led by ORI Healthcare Fund with participation from Perseverance Capital Management, reflecting investor confidence in the company's platform and leadership. The company is headquartered in Santa Ana, California. Cold Genesys is a clinical-stage immuno-oncology company focused on developing oncolytic immunotherapies, principally CG0070. CG0070 is an investigational oncolytic immunotherapy based on a modified common cold virus backbone that contains a cancer-specific promoter and a GM-CSF transgene and is designed to selectively replicate in tumors and elicit an immune response. The agent is intended to lyse tumor cells and induce immunogenic cell death, releasing tumor-derived antigens and GM-CSF to stimulate a systemic anti-tumor immune response. CG0070 is being evaluated in a pivotal Phase II single-arm, open-label BOND II study enrolling 122 high-risk non-muscle invasive bladder cancer patients who have failed BCG therapy and refused cystectomy. Cold Genesys plans to use financing proceeds to develop CG0070 in combination with immune checkpoint modulators across multiple Phase I/II studies for different solid tumor indications. The company acquired exclusive worldwide rights to CG0070 from BioSante Pharmaceuticals in 2010. The recent financing will support the pivotal trial and the company's combination-development programs.

No current team members are available.